Headlines about Tandem Diabetes Care (NASDAQ:TNDM) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.5184548783127 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Tracking Technical Indicators on Tandem Diabetes Care, Inc. (TNDM) – Wall Street Morning (wallstreetmorning.com)
- Tandem Diabetes Care (TNDM) Downgraded to Sell at ValuEngine (americanbankingnews.com)
- Tandem Diabetes Care Inc (TNDM) Director Dick Allen Purchases 25,539 Shares (americanbankingnews.com)
- Tandem Diabetes Care Announces Upcoming Conference Presentations (finance.yahoo.com)
- Tandem Diabetes Care (TNDM) Upgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
A number of analysts have recently weighed in on TNDM shares. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Wednesday, December 6th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 target price on shares of Tandem Diabetes Care in a research report on Friday, March 2nd. ValuEngine downgraded shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Wednesday. Oppenheimer started coverage on shares of Tandem Diabetes Care in a research report on Monday, February 26th. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Citigroup started coverage on shares of Tandem Diabetes Care in a research report on Tuesday, February 27th. They issued an “outperform” rating and a $5.50 target price on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $9.25.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, March 1st. The medical device company reported ($1.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.13). The company had revenue of $40.00 million for the quarter, compared to the consensus estimate of $38.41 million. During the same quarter last year, the business earned ($0.48) earnings per share. The business’s revenue was up 61.3% compared to the same quarter last year. equities analysts predict that Tandem Diabetes Care will post -2.36 earnings per share for the current fiscal year.
In other news, Director Dick Allen acquired 25,539 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average cost of $3.88 per share, with a total value of $99,091.32. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher J. Twomey acquired 75,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average cost of $2.00 per share, for a total transaction of $150,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 850,539 shares of company stock worth $1,749,091 over the last three months. 20.90% of the stock is currently owned by insiders.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.